PDF factsheet
      Z

All mechanism in obesity and overweight for all type of patients, clinical trials results

Bupropion versus placebo
Anderson, 2002
bupropion SR 300, or 400 mg/d.
versus
placebo
obese adults double-blind
Follow-up duration: 24 weeks
Croft, 2002
Bupropion, 300 mg for 44 wk
versus
Placebo
patients with major depression responder to open-label treatment with bupropion SR double-blind
Follow-up duration: 44 weeks
Jain, 2002
bupropion SR 300 mg/d
versus
Placebo
Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) double-blind
Follow-up duration: 26 weeks
Fluoxetine versus placebo
Breum, 1995
Fluoxetine, 60 mgfor 52 wk
versus
Placebo
aaaa
Connolly, 1995
fluoxetine 60 mg daily
versus
placebo
obese elderly patients over 60 years of age with Type 2 diabetes double-blind
Darga, 1991
fluoxetine
versus
placebo
obese subjects
Follow-up duration: 52 weeks
Goldstein, 1994
Fluoxetine, 60 mgfor 52 wk
versus
Placebo
obese outpatients double-blind
Follow-up duration: 52-week
Gray, 1992
Fluoxetine, 60 mg for 6 mo
versus
Placebo
obese, type 2 non-insulin dependent diabetics being treated with insulin double blind
Follow-up duration: 24 weeks
Marcus, 1990
Fluoxetine, 60 mgfor 52 wk
versus
Placebo
Mendoza Espejo, 1995
Fluoxetine, 180 mgfor 6 mo
versus
Placebo
Michelson 50wk, 1999
Fluoxetine, 20 mgfor 50 wk
versus
Placebo
O’Kane, 1994

versus
liraglutide versus placebo
Astrup (NN8022-1807 ), 2009
NCT00422058
4 liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg daily)
versus
placebo
obese individuals without type 2 diabetesdouble blind
Follow-up duration: 20 weeks
Europe
lorcaserin versus placebo
APD356-004, 2009

versus
BLOOM, 2010
NCT00395135
lorcaserin 10mg bid
versus
placebo
double-blind
Follow-up duration: 52 weeks
BLOOM-DM (10mg bid),
NCT00603291
lorcaserin 10 mg BID
versus
placebo
overweight and obese patients with type 2 diabetes mellitus managed with oral hypoglycemic agentsdouble-blind
Follow-up duration: 52 weeks
BLOSSOM (10mg bid), 2009
NCT00603902
lorcaserin 10 mg twice daily
versus
placebo
obese and overweight patients double blind
Follow-up duration: 1 year
USA
Orlistat versus placebo
Bakris, 2002
orlistat
versus
placebo
obese individuals with inadequately controlled hypertension. double-blind
Follow-up duration: 1-year
Broom, 2002
orlistat
versus
placebo
obese patients with cardiovascular riskdouble-blind
Follow-up duration: 54-week
Broom,, 2001

versus
Davidson, 1999
orlistat, 120 mg 3 times a day, for 52 weeks
versus
placebo
Obese adults (BMI 30-43 kg/m2) double-blind
Follow-up duration: 52 weeks
US
Deerochanawong,, 2001

versus
Derosa, 2003
orlistat 120 mg TID
versus
placebo
obese patients with hypercholesterolemia double-blind
Follow-up duration: 1-year
Gotfredsen, 2001

versus
Halpern, 2003
orlistat (120 mg t.i.d.),
versus
placebo
Obese, non-insulin-dependent diabetic patients, aged 18-70 years old, with BMI > 27 kg/m2Double-blind
Follow-up duration: 24 weeks
Latin-America
Hanefeld, 2002
orlistat 120 mg t.i.d.
versus
placebo
Overweight or obese adults (BMI >or= 28 kg/m2) with HbA1c of 6.5-11% and clinical type 2 diabetes double-blind
Follow-up duration: 48-week
Hauptman, 2000
60 mg of orlistat TID or 120 mg of orlistat TID,
versus
placebo
obese patients (BMI 30-44 kg/m2)double-blind
Follow-up duration: 1 year
USA
Hill, 1999
30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y
versus
placebo
Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapydouble-blind
Follow-up duration: 1 year
Hollander, 1998
120 mg orlistat orally three times a day
versus
placebo
obese men and women with type 2 diabetes who were aged > 18 years, had a BMI of 28-40 kg/m2, and were clinically stable on oral sulfonylureasdouble-blind
Follow-up duration: 57-week
Karhunen, 2000
orlistat 120 mg t.i.d.
versus
placebo
obese subjects double-blind
Follow-up duration: 1 y.
Kelley, 2002
orlistat 120 mg three times a day
versus
placebo
overweight or obese adults (BMI 28-40 kg/m(2)) with type 2 diabetes treated with insulin alone or combined with oral agents, but with suboptimal metabolic control (HbA(1c) 7.5-12.0%)double-blind
Follow-up duration: 1-year
Krempf, 2005
orlistat 120 mg three times daily
versus
placebo
otherwise healthy, overweight patients aged 18-65 y (BMI >or=28 kg/m2double-blind
Follow-up duration: 18-month
Lindgarde, 2000
orlistat 120 mg three times daily
versus
placebo
obese adults (body mass index 28-38 kg m-2) with type 2 diabetes, hypercholesterolaemia and/or hypertension double-blind
Follow-up duration: 1 year
Sweden
Lucas, 2003

versus
Micic, 1999
orlistat 120 mg three times daily
versus
placebo
obese patients (BMI > or = 30 kg/m2) with hyperlipidemia (LDL-cholesterol > or = 4, 2 mmol/l) double-blind
Follow-up duration: 24 weeks
Miles, 2002
120 mg orlistat t.i.d.
versus
placebo
overweight and obese patients with suboptimal control of type 2 diabetesdouble-blind
Follow-up duration: 1 year
Muls, 2001
orlistat 120 mg three times daily
versus
placebo
obese hypercholesterolemic patients, BMI between 27-40 kg/m2 and low-density-lipoprotein cholesterol, LDL-C, between 4.1-6.7 mmol/ldouble-blind
Follow-up duration: 24 week
Naumov, 2002
orlistat
versus
diet alone
patients with stable angina pectoris concomitant with obesity and hyperlipemiaopen
Reaven, 2001

versus
Rissanen, 2001
orlistat 120 mg three times daily
versus
placebo
healthy obese womendouble-blind
Follow-up duration: 12-month
Rosenfalck, 2002

versus
obese patients
Rossner, 2000
orlistat (60 or 120 mg) three times a day
versus
Obese patients (body mass index 28 to 43 kg/m2)
Obese patients (body mass index 28 to 43 kg/m2)double-blind
Follow-up duration: 2-year
Shi Yi, 2001

versus
Sjostrom, 1998
orlistat 120 mg (three times a day)
versus
double-blind
Follow-up duration: 1 year
Europe
Vidgren, 1999
120 mg of orlistat three times a day
versus
placebo
obese subjects
Follow-up duration: 1 year
PHEN/TPM high dose versus placebo
CONQUER (high-dose) (OB 303), 0
NCT00553787
PHEN/TPM 15/92 mg
versus
placebo

Follow-up duration: 56 weeks
OB 301 (high-dose), 0
PHEN/TPM 15/92 mg
versus
placebo

Follow-up duration: 28 weeks
OB 302 (high-dose), 0
PHEN/TPM 15/92 mg
versus
placebo

Follow-up duration: 56 weeks
PHEN/TPM low-dose versus placebo
OB 302 (low-dose), 0
PHEN/TPM 3.75/23 mg
versus
placebo

Follow-up duration: 56 weeks
PHEN/TPM mid-dose versus placebo
CONQUER (mid-dose) (OB 303),
NCT00553787
PHEN/TPM 7.5/46 mg
versus
placebo

Follow-up duration: 56 weeks
OB 301 (mid-dose), 0
PHEN/TPM 7.5/46 mg
versus
placebo

Follow-up duration: 28 weeks
sibutramine versus placebo
SCOUT, 2010
NCT00234832
sibutramine
versus
placebo
overweight or obese patients with diabetes or a history of coronary or peripheral vascular disease or stroke, along with other CV risk factorsdouble blind
Follow-up duration: 3.4 year
Sibutramine versus placebo
McMahon, 2002

versus
McMahon, 2000

versus
Smith, 2001

versus
tesofensine versus placebo
Astrup, 0

versus
Topiramate versus placebo
Bray, 2003

versus
Caterson, 2003

versus
Pud’homme, 2003

versus
Rissanen, 2003

versus
Stenlof, 2003

versus
Tonstad, 2003

versus

  Options


in first

in second

  Filter